Gynecologic Cancer Clinical Trial
— PROOFOfficial title:
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery - PROOF Prospective Cohort Study
This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.
Status | Recruiting |
Enrollment | 225 |
Est. completion date | November 30, 2033 |
Est. primary completion date | November 30, 2033 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18 years or greater - Undergoing evaluation for a newly diagnosed gynecologic malignancy - Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it Exclusion Criteria: - Contraindication to any study-related procedure or assessment - Does not speak a language for which the consent form and study materials are available |
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | American Society of Clinical Oncology, Conquer Cancer Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of participants who are categorized as frail | The Fried frailty phenotype (FP) assesses physical frailty through five criteria: unintentional weight loss; weakness or poor handgrip strength; self-reported exhaustion; slow walking speed; and low physical activity. Participants who receive a score of >3 will be categorized as 'frail'. Participants who receive a score <=3 will be categorized as Non-frail at time of enrollment. | At time of enrollment, 1 day | |
Primary | Demographic risk factors associated with those who screen positive for frailty | Demographic risk factors obtained from medical record review (i.e. sex, age, race, ethnicity, cancer type, cancer histology, cancer stage, comorbidities, etc.) will be assessed and analyzed for differences between participants categorized as frail versus non-frail. | At time of enrollment, 1 day | |
Primary | Oncologic risk factors associated with those who screen positive for frailty | Risk factors determined to be oncologic in nature will be assessed and analyzed for differences between participants categorized as frail versus non-frail. | At time of enrollment, 1 day | |
Secondary | Mean number of healthy days at home | The number of healthy days at home is defined as healthy days at home is defined as: 365 days minus (1) mortality days, (2) total number of days spent in inpatient, observation, skilled nursing facilities (SNF), rehabilitation, long-term hospital settings, emergency department and will be summarized and used as covariate in analysis. | Up to 10 years | |
Secondary | Mean length of hospital stay | The number of days participants stay in the hospital following standard of care surgery for gynecological cancer will be summarized and used as covariate in analysis. | Up to 10 years | |
Secondary | Percentage of participants readmitted to hospital | Participants with documented re-admission to a hospital following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis. | Up to 10 years | |
Secondary | Percentage of participants with reported surgical complications | Participants with documented peri-operative complications following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis. | Up to 10 years | |
Secondary | Mean time to initiation of standard of care chemotherapy | The median number of days following standard of care surgery for gynecological cancer to first standard of care chemotherapy initiation will be summarized and used as a covariate in analysis. | Up to 10 years | |
Secondary | Median Progression Free Survival (PFS) | Progression free survival is defined as the time from date of diagnosis to date of radiographic progression, and/or doubling of cancer antigen 125 (CA-125) from baseline. | Up to 10 years | |
Secondary | Median Overall Survival (OS) | Overall survival as defined by days from date of diagnosis to date of death, or study completion whichever occurs first. | Up to 10 years | |
Secondary | Mean number of treatment delays | Chemotherapy delays is defined by the number of chemotherapy infusions that are delayed due for medical purposes and the total number of days infusions are delayed for will be summarized and used as a covariate in analysis. | Up to 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Recruiting |
NCT05478876 -
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract
|
N/A | |
Active, not recruiting |
NCT04899492 -
Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery
|
N/A | |
Terminated |
NCT03658109 -
Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone
|
Early Phase 1 | |
Recruiting |
NCT05296512 -
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06398314 -
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors
|
N/A | |
Completed |
NCT01679483 -
Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer
|
N/A | |
Completed |
NCT01444924 -
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery
|
Phase 2 | |
Recruiting |
NCT05053230 -
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
|
N/A | |
Recruiting |
NCT04534075 -
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
|
Phase 3 | |
Active, not recruiting |
NCT04584957 -
Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.)
|
N/A | |
Completed |
NCT03292328 -
Yoga for Symptoms of Nerve Damage Caused by Chemotherapy
|
N/A | |
Completed |
NCT02459301 -
A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
|
Phase 1 | |
Completed |
NCT05131490 -
Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients
|
N/A | |
Active, not recruiting |
NCT03899376 -
A Trial Comparing Acute Toxicity in Patients With Gynecological Cancer Treated With VMAT
|
N/A | |
Not yet recruiting |
NCT05407987 -
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
|
Phase 3 | |
Recruiting |
NCT05891470 -
To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT
|
N/A | |
Not yet recruiting |
NCT05974995 -
Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer
|
N/A | |
Withdrawn |
NCT04368130 -
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
|
N/A |